Related Experiment Video
Updated: Jul 12, 2026

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
Published on: August 2, 2016
Programmed drug delivery system based on optimized "size decrease and hydrophilicity/hydrophobicity transformation"
Yuanyuan Liu1, Lian Li1, Lijia Li1
1Key Laboratory of Drug Targeting and Drug Delivery System (Ministry of Education), West China School of Pharmacy, Sichuan University, No. 17, Block 3, South Renmin Road, Chengdu 610041, P.R. China.
A novel drug delivery system, gelatin nanoparticle-doxorubicin-lactose (GNPs-Dox-Lac), overcomes barriers for enhanced hepatocellular carcinoma (HCC) therapy. This system achieved a 90.8% tumor inhibition rate with minimal toxicity in vivo.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Drug Delivery Systems
Background:
- Drug delivery systems face challenges with pathophysiological barriers, particularly concerning size and hydrophilicity/hydrophobicity.
- Optimizing these properties is crucial for effective therapeutic delivery, especially in complex diseases like cancer.
Purpose of the Study:
- To develop a programmed drug delivery system (GNPs-Dox-Lac) that addresses the size and hydrophilicity/hydrophobicity contradictions.
- To evaluate the efficacy and safety of GNPs-Dox-Lac for hepatocellular carcinoma (HCC) treatment.
Main Methods:
- Combination of gelatin nanoparticles (GNPs) with a doxorubicin-lactose (Dox-Lac) prodrug.
- Characterization of GNPs-Dox-Lac size (133.3 nm) and stability in circulation.
- Assessment of tumor site accumulation, MMP2-triggered prodrug release, pH-responsive dissociation, and in vivo tumor inhibition.
Main Results:
- GNPs-Dox-Lac demonstrated kinetic stability in blood and preferential accumulation at tumor sites.
- Tumor extracellular matrix metalloproteinase-2 (MMP2) triggered the release of Dox-Lac (898 Da), facilitating tissue penetration and cellular uptake.
- Intracellular pH-responsive dissociation of Dox-Lac released free doxorubicin (543 Da), inducing targeted toxicity.
- Achieved a superior tumor inhibition rate of 90.8% with low observed toxicity in vivo.
Conclusions:
- The developed GNPs-Dox-Lac system effectively overcomes drug delivery barriers through optimized size and hydrophilicity/hydrophobicity.
- This programmed delivery approach shows significant potential for enhancing doxorubicin efficacy in hepatocellular carcinoma (HCC) therapy with improved safety.
- Further investigation is warranted for clinical translation of this advanced nanomedicine approach.
More Related Videos
10:16Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
Published on: February 8, 2017
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
Modified-Release Drug Delivery Systems: Rate-Programmed II
Drug Delivery Systems: Different Types
Modified-Release Drug Delivery Systems: Classification
Modified-Release Drug Delivery Systems: Rate-Programmed I
Modified-Release Drug Delivery Systems: Site-Targeted
Site-Targeted Drug Delivery Systems: Polymeric Carriers